Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment DOI
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(8), С. 487 - 503

Опубликована: Март 17, 2023

Язык: Английский

Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells DOI Open Access
Benjamin Ruf, Bernd Heinrich, Tim F. Greten

и другие.

Cellular and Molecular Immunology, Год журнала: 2020, Номер 18(1), С. 112 - 127

Опубликована: Ноя. 24, 2020

Язык: Английский

Процитировано

240

Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity DOI
Hirofumi Hirao, Kojiro Nakamura, Jerzy W. Kupiec‐Weglinski

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2021, Номер 19(4), С. 239 - 256

Опубликована: Ноя. 26, 2021

Язык: Английский

Процитировано

234

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort DOI
Tracey G. Simon, Björn Roelstraete, Hannes Hagström

и другие.

Gut, Год журнала: 2021, Номер 71(9), С. 1867 - 1875

Опубликована: Сен. 6, 2021

Objective Some data suggest a positive association between non-alcoholic fatty liver disease (NAFLD) and incident major adverse cardiovascular events (MACEs). However, are lacking from large cohorts with histology, which remains the gold standard for staging NAFLD severity. Design This population-based cohort included all Swedish adults histologically confirmed without (CVD) at baseline (1966–2016, n=10 422). was defined prospectively recorded histopathology categorised as simple steatosis, non-fibrotic steatohepatitis, non-cirrhotic fibrosis cirrhosis. Patients were matched to ≤5 population controls or CVD, by age, sex, calendar year county (n=46 517). Using Cox proportional hazards modelling, we calculated multivariable adjusted HRs (aHRs) 95% CIs MACE outcomes (ie, ischaemic heart (IHD), stroke, congestive failure (CHF) (CV) mortality). Results Over median of 13.6 years, in 2850 patients 10 648 controls. had higher incidence than (24.3 vs 16.0/1000 person-years (PY); difference=8.3/1000 PY; aHR 1.63, CI 1.56 1.70), including rates IHD (difference=4.2/1000 1.64, 1.54 1.75), CHF (difference=3.3/1000 1.75, 1.63 1.87), stroke (difference=2.4/1000 1.58, 1.46 1.71) CV mortality (difference=1.2/1000 1.37, 1.27 1.48). Rates increased progressively worsening severity (p trend =0.02), highest observed cirrhosis (difference controls=27.2/1000 2.15, 1.77 2.61). Conclusion Compared controls, biopsy-proven significantly MACE, IHD, mortality. Excess risk evident across stages

Язык: Английский

Процитировано

211

Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease DOI Open Access
Francesco Violi, Vittoria Cammisotto,

Simona Bartimoccia

и другие.

Nature Reviews Cardiology, Год журнала: 2022, Номер 20(1), С. 24 - 37

Опубликована: Июль 15, 2022

Язык: Английский

Процитировано

196

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment DOI
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(8), С. 487 - 503

Опубликована: Март 17, 2023

Язык: Английский

Процитировано

195